Both inhibitors strongly reduced the damage-associated upregulation of P-ERK1/2 in MG by up to 83% (DEV 2: PD153035, N = 5, P < 0.001; PD158780, N = 4, P < 0.001, Fig. 6b, S6). This evidence concerns the gene MAPK3 and myasthenia gravis.